Platinum IV complex inhibitor

Details Platinum IV complex inhibitor Platinum IV complex inhibitor

2005-12-23

2010-10-05

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S184000, C514S202000

Reexamination Certificate

active

07807662

ABSTRACT:
The invention disclosed herein provides methods for diagnosing and treating diseases and/or conditions associated with dysregulated Stat3-mediated activity.

REFERENCES:
patent: 2004/0097423 (2004-05-01), Siddik et al.
patent: 2006/0030536 (2006-02-01), Yu et al.
patent: WO-2006/071812 (2006-07-01), None
Akira, S. (2000). “Roles of STAT3 Defined by Tissue-Specific Gene Targeting,”Oncogene19:2607-2611.
Allain, P. et al. (2000). “Early Biotransformations of Oxaliplatin After its Intravenous Administration to Cancer Patients,”Drug Metab Dispos28(11):1379-1384.
Becker, S. et al. (1998). “Three-Dimensional Structure of the Stat3β Homodimer Bound to DNA,”Nature394:145-151.
Bose, R.N. (2002). “Biomolecular Targets for Platinum Antitumor Drugs,”Mini. Rev. Med. Chem. 2(2):103-111.
Bowman, T. et al. (Jun. 19, 2001). “Stat3-Mediated Myc Expression is Required for Src Transformation and PDGF-Induced Mitogenesis,”Proc. Natl. Acad. Sci. U. S. A. 98(13):7319-7324.
Bowman, T. et al. (2000). “STATs in Oncogenesis,”Oncogene19:2474-2488.
Bromberg, J. (2000). “Signal Transducers and Activators of Transcription as Regulators of Growth, Apoptosis and Breast Development,”Breast Cancer Res. 2:86-90.
Bromberg, J. F. et al. (May 1998). “Stat3 Activation is Required for Cellular Transformation by v-src,” Mol. Cell. Biol. 18(5):2553-2558.
Bromberg, J. F. et al. (Jul. 1996). “Transcriptionally Active Stat1 is Required for the Antiproliferative Effects of Both Interferon α and Interferon γ,”Proc. Natl. Acad. Sci. USA93:7673-7678.
Bromberg, J. F. et al. (Aug. 6, 1999). “Stat3as an Oncogene,”Cell98:295-303.
Buettner, R. et al. (Apr. 2002). “Activated STAT Signaling in Human Tumors Provides Novel Molecular Targets for Therapeutic Intervention,”Clin. Cancer Res. 8:945-954.
Catlett-Falcone, R. et al. (Jan. 1999). “Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells,”Immunity10:105-115.
Coffer, P. J. et al. (2000). “The Role of STATs in Myeloid Differentiation and Leukemia,”Oncogene19:2511-2522.
Darnell, J. E., Jr. (Sep. 12, 1997). “STATs and Gene Regulation,”Science277:1630-1635.
Darnell, J. E., Jr. (Oct. 2002). “Transcription Factors as Targets for Cancer Therapy,”Nat. Rev. Cancer2:740-749.
Darnell, J. E., Jr. et al. (Jun. 3, 1994). “Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins,”Science264:1415-1421.
Epling-Burnette, P. K. et al. (Feb. 2001). “Inhibition of STAT3 Signaling Leads to Apoptosis of Leukemic Large Granular Lymphocytes and Decreased Mcl-1 Expression,”J. Clin. Invest. 107(3):351-362.
Fukada, T. et al. (Nov. 1996). “Two Signals are Necessary for Cell Proliferation Induced by a Cytokine Receptor gp130: Involvement of STAT3 in Anti-Apoptosis,”Immunity5:449-460.
Garcia, R. et al. (2001). “Constitutive Activation of Stat3 by the Src and JAK Tyrosine Kinases Participates in Growth Regulation of Human Breast Carcinoma Cells,”Oncogene20:2499-2513.
Garcia, R. et al. (Dec. 1997). “Constitutive Activation of Stat3 in Fibroblasts Transformed by Diverse Oncoproteins and in Breast Carcinoma Cells,”Cell Growth Diff. 8:1267-1276.
Gouilleux, F. et al. (1995). “Prolactin and Interleukin-2 Receptors in T Lymphocytes Signal through a MFG-STAT5-Like Transcription Factor,”Endocrinology136(12):5700-5708.
Grandis, J. R. et al. (Apr. 11, 2000). “Constitutive Activation of Stat3 Signaling Abrogates Apoptosis in Squamous Cell Carcinogenesis in Vivo,”Proc. Natl. Acad. Sci. U.S.A. 97(8):4227-4232.
Heudi, O. et al. (2001). “Chemical Instability and Methods for Measurement of Cisplatin Adducts Formed by Interactions with Cysteine and Glutathione,”Int J Clin Pharmacol Ther39(8):344-349.
Heudi, O. et al. (1999). “Mechanisms of Reaction of L-Methionine with Carboplatin and Oxaliplatin in Different Media: a Comparison with Cisplatin,”Biopharm Drug Dispos20:107-116.
Hirano, T. et al. (2000). “Roles of STAT3 in Mediating the Cell Growth, Differentiation and Survival Signals Relayed Through the IL-6 Family of Cytokine Receptors,”Oncogene19:2548-2556.
Johnson, P. J. et al. (May 1985). “Overexpressed pp60c-srcCan Induce Focus Formation Without Complete Transformation of NIH 3T3 Cells,”Mol. Cell. Biol. 5(5):1073-1083.
Kotenko, S. V. et al. (2000). “Jak-Stat Signal Transduction Pathway Through the Eyes of Cytokine Class II Receptor Complexes,”Oncogene19:2557-2565.
Lin, T. S. et al. (2000). “STAT Signaling in the Pathogenesis and Treatment of Leukemias,”Oncogene19:2496-2504.
Mora, L. B. et al. (Nov. 15, 2002). “Constitutive Activation of Stat3 in Human Prostate Tumors and Cell Lines: Direct Inhibition of Stat3 Signaling Induces Apoptosis of Prostate Cancer Cells,”Cancer Res62:6659-6666.
Nielsen, M. et al. (1999). “Inhibition of Constitutively Activated Stat3 Correlates with Altered Bcl-2/Bax Expression and Induction of Apoptosis in Mycosis Fungoides Tumor Cells,”Leukemia13:735-738.
Nielsen, M. et al. (Jun. 1997). “Constitutive Activation of a Slowly Migrating Isoform of Stat3 in Mycosis Fungoides: Tyrphostin AG490 Inhibits Stat3 Activation and Growth of Mycosis Fungoides Tumor Cell Lines,”Proc. Natl. Acad. Sci. USA94:6764-6769.
Niu, G. et al. (Oct. 15, 1999). “Gene Therapy with Dominant-Negative Stat3 Suppresses Growth of the Murine Melanoma B16 Tumor in vivo,”Cancer Res. 59:5059-5063.
Oshiro, M. M. et al. (Dec. 2001). “Inhibition of JAK Kinase Activity Enhances Fas-Mediated Apoptosis but Reduces Cytotoxic Activity of Topoisomerase II Inhibitors in U266 Myeloma Cells,”Clin. Cancer Res. 7:4262-4271.
Oyajobi, B. O. et al. (Jul. 1, 2003). “Dual Effects of Macrophage Inflammatory Protein-1α on Osteolysis and Tumor Burden in the Murine 5TGM1 Model of Myeloma Bone Disease,”Blood102(1): 311-319.
Perez, J. M. et al. (2003). “Antitumor and Cellular Pharmacological Properties of a Novel Platinum(IV) Complex:trans-[PtCl2(OH)2(Dimethylamine) (Isopropylamine)],”Mol Pharmacol63(4):933-944.
Persons, D. L. et al. (May 1999). “Cisplatin-Induced Activation of Mitogen-Activated Protein Kinases in Ovarian Carcinoma Cells: Inhibition of Extracellular Signal-Regulated Kinase Activity Increases Sensitivity to Cisplatin,”Clin. Cancer. Res. 5:1007-1014.
Sanchez-Perez, I. et al. (1998). “Cisplatin Induces a Persistant Activation of JNK that is Related to Cell Death,”Oncogene16:533-540.
Schindler, C. et al. (1995). “Transcriptional Responses to Polypeptide Ligands: the JAK-Stat Pathway,”Annu. Rev. Biochem. 64:621-651.
Seidel, H. M. et al. (Mar. 1995). “Spacing of Palindromic Half Sites as a Determinant of Selective STAT (Signal Transducers and Activators of Transcription) DNA Binding and Transcriptional Activity,”Proc. Natl. Acad. Sci. U. S. A. 92:3041-3045.
Siddik, Z. H. (2003). “Cisplatin: Mode of Cytotoxic Action and Molecular Basis of Resistance,”Oncogene22: 7265-7279.
Sinibaldi, D. et al. (2000). “Induction of p21WAF1/CIP1 and Cyclin D1 Expression by the Src Oncoprotein in Mouse Fibroblasts: Role of Activated STAT3 Signaling,”Oncogene19:5419-5427.
Smithgall, T. E. et al. (2000). “Control of Myeloid Differentiation and Survival by Stats,”Oncogene19:2612-2618.
Song, J. I. et al. (2000). “STAT Signaling in Head and Neck Cancer,”Oncogene19:2489-2495.
Song, L. et al. (2003). “Activation of Stat3 by Receptor Tyrosine Kinases and Cytokines Regulates Survival in Human Non-Small Cell Carcinoma Cells,”Oncogene22:4150-4165.
Stark, G. R. et al. (1998). “How Cells Respond to Interferons,”Annu. Rev. Biochem. 67:227-264.

Affiliated with

Also associated with

Rating

Platinum IV complex inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Platinum IV complex inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platinum IV complex inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4165708